Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 10/20 | 0.35 |
| ▸ | TP53 | P04637 | 9/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319230 | 0.90 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6916644 | 0.89 | MDM2 (0.40) | DRD2OPRM1DRD3MDM2TP53 | |
| SCHEMBL1709466 | 0.88 | MDM2 (0.41) | DRD2OPRM1DRD3MDM2TP53 | |
| SCHEMBL13964536 | 0.87 | DRD2 (0.45) | DRD2OPRM1DRD3MDM2TP53 | |
| SCHEMBL2313658 | 0.84 | PSEN1 (0.41) | DRD2OPRM1DRD3MDM2TP53 | |
| SCHEMBL2316326 | 0.83 | PSEN1 (0.42) | MDM2TP53PSEN1PSEN2APH1B | |
| SCHEMBL2316485 | 0.83 | PSEN1 (0.40) | DRD2OPRM1DRD3PSEN1PSEN2 | |
| SCHEMBL13964539 | 0.82 | PSEN1 (0.40) | MDM2TP53PSEN1PSEN2APH1B | |
| SCHEMBL6917637 | 0.82 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2317127 | 0.81 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528890-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | claimed |
| WO-2011092611-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-08-04 | — | — | WO | claimed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011092611-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | DRD2 1417/4885OPRM1 1137/4885DRD3 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.